Compare Abeona Therapeutics Inc (ABEO) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TKO Group Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while TKO Group Holdings Inc trades at $192.01 (market cap $14.51B). The key difference: TKO Group Holdings Inc is far larger — about 38.9× Abeona Therapeutics Inc's market cap, and TKO Group Holdings Inc pays a 1.61% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TKO | |
|---|---|---|
Market Cap | $373.32M | $14.51B |
Sector | Health | Technology |
52-Week High | $7.23 | $224.96 |
52-Week Low | $4.17 | $155.61 |
Enterprise Value | $228.22M | $18.69B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TKO trades at $192.30, down 1.09% today, with a bearish technical signal. The stock shows mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with net income of $195.40M, though high P/E of 71.49 suggests premium valuation. Recent news includes a successful WWE-UFC doubleheader and an $800M share repurchase, indicating strong operational momentum.
Outlook remains positive with 84% analyst buy ratings and a $234 consensus target, but risks include earnings volatility and competitive pressures. The stock offers growth potential through live event demand and media deals, yet investors should monitor margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
